BRC
TEVA icon

Blue Ridge Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Blue Ridge Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,415,000
Closed -$71.1M – 60
2016
Q2 		$71.1M Sell
1,415,000
-2,573,300
-65% -$137M 0.92% 35
2016
Q1 		$213M Sell
3,988,300
-11,700
-0.3% -$686K 2.59% 14
2015
Q4 		$263M Buy
+4,000,000
New +$247M 2.92% 12

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Blue Ridge Capital's TEVA Position: Q3 2016 in Review

Blue Ridge Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 1,415,000 shares — an estimated $71.1M sold.

Blue Ridge Capital first reported a position in TEVA in Q4 2015 and held it in 3 quarters. The position peaked at $263M in Q4 2015. 795 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

  • Blue Ridge Capital reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Blue Ridge Capital sold 1,415,000 Teva Pharmaceuticals shares in Q3 2016, an estimated $71.1M.
  • Blue Ridge Capital first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Blue Ridge Capital's Teva Pharmaceuticals position peaked at $263M in Q4 2015.
  • 795 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Blue Ridge Capital's 13F filing for Q3 2016, filed 14 Nov 2016.